PTC Therapeutics announced today the results of its real-world study for patients diagnosed with Becker muscular dystrophy (BMD) and Duchenne muscular dystrophy (DMD) who switched between prednisone to EMFLAZA® (deflazacort) after the U.S. Food and Drug Administration’s (FDA) approval. The data was presented at the 2021 Muscular Dystrophy Association (MDA) Virtual Clinical and Scientific Conference. Majority of the patients that switched to EMFLAZA from prednisone was the desire to delay the progression of the disease and to improve the benefits and tolerability.

Read more here.

More on: